Third Harmonic Bio Initiates Strategic Review, Lays Off 50% Staff Citing Competitive Landscape
Third Harmonic Bio, Inc. (NASDAQ:THRD) revealed results from its Phase 1 single and multiple ascending dose (SAD/MAD) trial ...
Hosted on MSN4d
Third Harmonic Bio, Inc. (THRD) Upgraded to Buy: What Does It Mean for the Stock?
Third Harmonic Bio, Inc. (THRD) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is ...
FierceBiotech7d
Third Harmonic halves headcount to take urticaria drug into phase 2 despite side effects
The MAD cohort also saw adverse events such as hair loss and reductions in hemoglobin and neutrophil counts. These side ...
Fintel on MSN6d
Morgan Stanley Downgrades Third Harmonic Bio (THRD)
Fintel reports that on February 12, 2025, Morgan Stanley downgraded their outlook for Third Harmonic Bio (NasdaqGM:THRD) from ...
Raymond James downgrades Third Harmonic Bio on uncertainty for only asset
As previously reported, Raymond James downgraded Third Harmonic Bio (THRD) to Market Perform from Outperform and removed the firm’s prior $18 ...
Third Harmonic Shares Dive As Evaluation of THB335 Begins
Third Harmonic Bio shares dived 35% in premarket trading amid a broader evaluation of THB335. Shares were trading around $3.03. The stock is down 50% over the last year.
Third Harmonic Bio downgraded to Equal Weight from Overweight at Morgan Stanley
Morgan Stanley downgraded Third Harmonic Bio (THRD) to Equal Weight from Overweight with a price target of $5, down from $20, after the company ...
Benzinga.com6d
Third Harmonic Bio Initiates Strategic Review, Lays Off 50% Staff Citing Competitive Landscape
Third Harmonic Bio will halt non-THB335 research and cut 50% of its workforce while reviewing strategic options. Get real-time earnings alerts before the market moves and access expert analysis ...